Decreasing IF1 levels in carcinomas reduces glycolysis and enhances OXPHOS, akin to the effects of oligomycin, leading to increased mitochondrial membrane potential, ETC stalling, and higher ROS production [15,45,57]. The gene discussed is ATP5IF1; the disease is carcinoma.